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Introduction
Idiopathic Pulmonary Fibrosis (IPF) is a chron-
ic, progressive and life-threatening disease of un-
known cause (1). Symptoms such as dyspnea, cough 
and fatigue lead to a reduction of daily physical ac-
tivities, exercise tolerance, muscle strength and qual-
ity of life (QOL). Problems reported by IPF patients 
are social isolation, increased level of dependency 
and immobility (1-5).
Pharmacologic treatment options are limited 
(5). There are two drugs that reduce pulmonary func-
tion decline in patients with IPF, however their ef-
fect on QoL is not convincingly established (6-8). In 
a selected, limited group of patients with IPF, lung 
transplantation can be an option. Non-pharmaco-
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Abstract. Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of pulmonary function and 
exercise capacity, leading to loss of quality of life and often social isolation. A new walking aid, the walk-bike, 
showed an improvement in exercise performance in COPD patients. Aims of this pilot study were to evaluate 
feasibility of a homebased walk-bike intervention study in IPF patients and to explore the effect of the walk-bike 
on quality of life (QoL) and exercise capacity. Twenty-three patients with IPF were included in a randomized 
multicenter crossover study with 8 weeks of standard care and 8 weeks of walk-bike use at home. Ten patients 
completed both study phases. Study barriers included reluctance to participate and external factors (e.g. weather 
and road conditions) that hampered adherence. Patients’ satisfaction and experience with the walk-bike varied 
greatly. After training with the walk-bike, health-related QoL (St. George’s Respiratory and  King’s Brief Inter-
stitial Lung Disease questionnaires) demonstrated a tendency towards improvement, exercise capacity did not. 
A clinically important difference was found between 6-minute walk test with the walk-bike and the standard 
test; median (range) respectively 602 m (358-684) and 486 m (382-510). Conclusions: Due to practical barriers 
a larger study with the walk-bike in patients with IPF seems not feasible. Individual patients may benefit from 
the use of a walk-bike as it improved action radius and showed a tendency towards improvement in QoL. No 
effect on exercise capacity was observed.  (Sarcoidosis Vasc Diffuse Lung Dis 2020; 37 (2): 192-202)
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logic treatments that could improve QoL are increas-
ingly investigated (4, 9-11). Pulmonary rehabilitation 
(PR) programs are recommended by expert opinion 
for the majority of IPF patients to improve QoL and 
exercise tolerance (1, 5, 12). Cochrane reviews on 
physical training in patients with different interstitial 
lung diseases (ILD), including IPF, indicate PR has 
a beneficial effect on QoL and functional exercise ca-
pacity in IPF patients (3, 13, 14). Another problem is 
that the long-term effects of PR are debated (15-20). 
Furthermore, PR programs are offered in outpatient 
clinics and specialized rehabilitation centers with 
a duration of usually 6 -12 weeks (14). Due to the 
limited life expectancy of IPF patients and practical 
problems with decreased mobility and transport, pa-
tients are often hesitant to participate in these exter-
nal programs. Therefore, in recent years home-based 
(supervised) training has become increasingly inves-
tigated (20-22). An earlier study has demonstrated 
that a new-walking aid, the walk-bike , improved 
exercise performance in Chronic Obstructive Pul-
monary Disease (COPD) patients due to the more 
efficient way of moving without excessive metabolic 
demand (23). To assess whether a study using this 
new method for homebased training is feasible and 
of benefit for IPF patients, we designed a crossover 
pilot study. We hypothesized that use of this walk-
bike in daily life extends the range and everyday mo-
bility of IPF patients, thereby decreasing the level of 
dependency and social isolation and improving QoL. 
If daily activities of IPF patients increase, exercise 
capacity might improve too. The objectives of this 
pilot study were (1) to evaluate the feasibility of a 
home-based walk-bike intervention study in IPF pa-
tients, and (2) to explore the effect of the walk-bike 
on QoL and exercise capacity.
Methods
Subjects
Patients were eligible to participate in this study 
if they were diagnosed with IPF according to the 
international guidelines criteria (1), had a diffusing 
capacity of the lung for carbon monoxide (TLCO) 
≥ 25% predicted, a Forced Vital Capacity (FVC) 
≥ 50% predicted, a 6-minute walk distance (6MWD) 
≥ 150 meters and were clinically stable without a de-
cline in TLCO and FVC of 10% or more in the past 
six months.
Exclusion criteria were participation in an of-
ficial rehabilitation program 4 months  preceding 
enrolment, musculoskeletal disorders, severe cardiac 
diseases (an ejection fraction < 30%, daily angina, or 
otherwise specified by treating cardiologist), unable 
to understand informed consent or other conditions 
that could hamper the use of a walk-bike. Patients 
were recruited at the outpatient clinics of three res-
piratory medicine departments in the Netherlands, 
Denmark and Spain (NTR5334, www.trialregister.
nl). The study was approved by ethic committees of 
all participating sites and all patients gave written 
informed consent to participate (MEC-2014-047, 
Erasmus University Medical Center).
Study design
This prospective multicenter pilot study fol-
lowed a 2-period crossover design with an interven-
tion period and a control period of each 8 weeks. The 
intervention was a home-based training program 
using a walk-bike in daily life during 8 weeks, with 
the aim of a minimum of 1 hour per day. Patients 
were asked to record the time of real use of the walk-
bike in a diary. At baseline, instructions and train-
ing were given. During the control period patients 
received standard treatment only. The walk-bike is 
an ambulation aid, a form of a bicycle but without 
pedals (Figure 1). By sitting on the seat the load on 
the muscles of ambulation is reduced which results in 
a lower cost of transport (oxygen uptake in mL/min 
per meter distance) (23).
Study procedure
Prior to randomization clinical stability was as-
sessed by the physician. Pulmonary function and ex-
ercise performance were tested by spirometry, TLCO 
and 6MWT. Patients were randomly allocated to 
start with the intervention- or control period by an 
independent research nurse not involved in the study 
and using sealed nontransparent envelopes. Block 
randomization was used to ensure that the numbers 
of participants assigned to each group were equal-
ly distributed during the different seasons. After 8 
weeks of intervention- or control period, patients 
were asked to cross over. Outcome variables were 
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measured at baseline, after 9 weeks and at the end 
of the study at 18 weeks. Pulmonary function tests 
including FVC and TLCO were done as part of the 
routine medical follow up of treatment. 
Feasibility outcomes
Outcomes of feasibility comprised the num-
ber of patients assessed for eligibility, the propor-
tion of patients that were randomized, the number 
of patients that finished both periods of the cross-
over study and adherence with the intervention (1 
hour use of the walk-bike per day). Throughout the 
study, comments and suggestions for improvement 
from patients and the medical team were collected 
to explore potential barriers of this study for future 
research. After the study, patients were asked about 
their experience and satisfaction with the use of the 
walk-bike. Feasibility outcomes of all patients that 
signed informed consent were used. 
Patient-reported outcomes
The primary outcome was change in total 
score in health-related QoL measured with the St. 
George’s Respiratory Questionnaire (SGRQ) af-
ter 8 weeks of standard of care and after 8 weeks of 
walk-bike use at home. Although designed for pa-
tients with obstructive disease, the SGRQ has been 
found to be a valid measure of health-related QoL in 
patients with restrictive disease including IPF (24, 
25).  A change of 7 points in SGRQ total score (0-
100) is known to be the minimal clinically important 
difference (MID) for IPF patients (26). Secondary 
outcome was change in total score of the disease-
specific King’s Brief Interstitial Lung disease health 
status questionnaire (K-BILD) (27). The MID range 
in ILD for the total score is 6-10 units (28).
 Other secondary outcomes are change in SGRQ 
and K-BILD domain scores, and in scores measured 
with the General Anxiety Disorder Screener (GAD-
7) (29).
Exercise capacity
Additional secondary outcomes were change 
in functional exercise capacity, determined by the 
6MWT (30) after 8 weeks of standard of care or 8 
weeks of walk-bike use at home, and change in the 
number of steps per day as a proxy for daily physical 
activities, measured with a pedometer (Yamax Digi-
walker SW-200)(31). To compare exercise perfor-
mance with or without the walk-bike, patients were 
asked to perform an additional 6MWT using the 
walk-bike, after the regular 6MWT. This was done 
at the visit after the intervention period (in week 9 or 
week 18 depending on allocation). The assessor that 
measured the regular 6MWT at 9 and 18 weeks was 
blinded for the allocation and patients were instruct-
ed not to inform the care provider. Patients were 
asked to wear the pedometer  for a week at baseline, 
at the crossover moment and after the study. 
Pulmonary function tests 
PFT’s were performed according to ATS/ERS 
2005 criteria(32, 33). FVC and TLCO were record-
ed and expressed as percentage of the predicted value 
(%pred).
Analysis
Due to the explorative nature of this pilot study, 
no sample size calculations were done and results 
are given in a descriptive way. As it concerns a small 
group of patients, results are described without sta-
tistical analysis. 
Fig. 1. Walk-bike
Effect of the walk-bike on QoL and 6MWT in IPF 195
Results
Feasibility outcomes
One hundred and twenty five outpatients with 
IPF were assessed for eligibility for the study, 23 
(18%) were interested in participating, signed in-
formed consent, and were randomized. Twelve pa-
tients were allocated to start in the intervention 
group and 11 patients to the control group. Sixteen 
patients finished the first phase of 8 weeks of the 
study and after crossover, 10 patients also completed 
the second phase. Two patients who started in the 
intervention group did not crossover because they 
wanted to continue using the walk-bike. Other rea-
sons for not completing the full protocol are shown 
in Figure 2.
Ten of the 14 patients that completed the walk-
bike period, recorded the actual use of the walk-bike 
in a diary; the median (min-max) use of the walk-
bike was 5.3 (2.0- 6.9) days a week and 43.9 (11.3-
60.6) minutes per actual usage day. An overview of 
potential barriers and solutions as reported by pa-
tients and medical staff during this study is provided 
in Table 1. 
Patient satisfaction and experience with the 
walk-bike are shown in Table 2. Comments differed 
from very satisfied with continuation of using the 
walk-bike after the study, to not satisfied because us-
ing the walk-bike was too heavy or because of feel-
ings of embarrassment. 
One patient reported two fall-incidents due to 
wet and slippery roads, without any physical com-
plaints, and decided to stop with the study. 
Explorative outcomes
Baseline characteristics (Table 3) demonstrate 
Fig. 2. Study flow chart of patients screened and enrolled
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that patients were predominantly male with a de-
creased FVC, TLCO, exercise tolerance and health-
related QoL. The patients who dropped out during 
the study showed on average worse scores in diffus-
ing capacity, exercise measures and health status. The 
results of the 10 patients that followed the complete 
protocol are given in Table 4 .
SGRQ- and K-BILD total score, as well as 
the domain scores, tended to improve after training 
with the bike (Figure 3), with the most striking im-
provement in SGRQ symptoms- and K-BILD chest 
scores.
No change after training was observed in the 
6MWD, the anxiety score or perceived health status 
(Table 4). 
A meaningful difference in distance covered 
was found between the 6MWT performed with the 
walk-bike and the unaided 6MWT with a median 
(min-max) 6MWD of 602 meters (358-684) vs. 486 
meters (382-510); (Figure 4). The lowest oxygen 
saturation during the 6MWT with the walk-bike 
and unaided did not differ with a nadir SpO2 of 86% 
(80-91) vs. 87% (78-90). 
During the study, the lung volume remained 
stable with a median (min-max) FVC at baseline of 
69%pred (53-87) vs. 70%pred (57-86) in week 18. 
Table 1. Overview of detected potential barriers for homebased use of the walk-bike for research as detected by patients and the medical 
team
Potential barriers Findings in this study Possible solutions 
Weather conditions Patients frequently recorded not using the bike due to rain, 
storm, snow, slipperiness, heat and humidity. 
Additionally offering a homebased 
indoor trainings program
Transport of oxygen device
(a small bottle of oxygen can be 
attached with Velcro to the rear of 
the frame below the saddle).
One patient stopped 1 week after the start because he 
experienced attaching the oxygen to the bike was too 
much hassle. Another patient solved her problem with 
transportation of the oxygen bottle by transporting a 
smaller oxygen device in a back pack.
Ask the vendor to add a larger 
basket at the rear of the bike to 
facilitate oxygen transport or 
providing the option of a back pack.
Hills and unpaved roads A patient recorded that even a minor hill makes using the 
walk-bike heavier than regular walking. Another patient 
mentioned the walk bike is most useful when the road is 
smooth or goes downhill and uphill, it is useful as a support 
object, like a walker.
Another patient living in the countryside stopped using the 
bike because it was too heavy to use on unpaved roads. 
The walk-bike seems more fit for 
paved roads and flat countries.  
The option of electrical support to 
switch on would be an option to 
overcome hills. 
Compliance/motivation Some patients were very compliant and recorded they used 
the bike every day for at least 60 minutes, others were 
hampered by external factors or symptoms and didn’t use 
the bike for days.
Using accelerometers and new 
e-health technologies may help the 
medical team to detect barriers in 
use of the walk-bike at an earlier 
stage enabling them to contact and 
coach or support the patient in 
finding solutions.
Fear of stigmatization Some patients didn’t want to participate as they (or their 
spouse) where being afraid to be stigmatized for using an 
assistive device. 
For some patients the potential 
benefit of the walk-bike will not 
outweigh the impact of making 
their disease visible by using an 
assistive device. Similar findings 
have been reported for ambulatory 
oxygen and careful discussion may 
help but in the end it is the patient 
who decides. 
Saddle pain Some patients were bothered by saddle pain or felt the 
saddle was uncomfortable
Provide silicone gel saddles
Limitations to use the walk bike in 
public places and public transport 
None of the patients mentioned these problems Patients were provided with a card 
that  the walk-bike is an assistive 
device in case they would get 
questions.  
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Table 2. Comments on the walk-bike
Positive comments
Bike is really good for training; feel fit after 8 weeks of training
Although not comfortable with the bike because of shoulder pain, would like to continue using it
Able to walk further with less dyspnea
Enables me to leave the house and e.g. go to the bakery without being dependent of my spouse
Easier and nicer to walk
Able to walk further; it is more comfortable and gives possibility to rest
The walk bike has been a good means of contact with other people, it has the interest of news.
Negative comments
Too heavy in combination with oxygen; difficult to use with oxygen bottle
Difficult way of making steps
Able to walk further because of better stability but feel embarrassed when using walk bike
Uncomfortable with bike, roads are too slippery
For small hills walking with the help of the walk-bike is more difficult than without
Table 3. Baseline characteristics of the study patients
Randomized  (N=23) Completed study (N=10) Drop outs (N=13)
Male 18 (78%) 8 (80%) 10 (77%)
Age (years) 71 (54-88) 71 (60-88) 72 (54-88)
Pulmonary function
FVC (%pred) 69 (48-97) 69 (53-87) 72 (48-97)
TLCO (%pred) 43 (26-67)* 51 (26-62) 40 (26-67)**
Exercise measures
6MWD (m) 443 (278-593)* 481 (360-540) 433 (278-593)**
Nadir SpO2 (%) 87 (78-96)* 89 (81-95) 85 (78-96)**
Average steps/day 3521 (478-9869)† 4016 (707-9636)ǁ 3185 (478-9869)††
Health status scores
SGRQ total [0-100]§§ 50 (16-62)‡ 44 (32-52)¶ 55 (16-62)‡‡
K-BILD total [0-100]ǁǁ 63 (30-83)* 66 (56-78) 58 (30-83)**
Perceived health status [1-5]¶¶ 3 (2-4)§ 3 (3-4) 3 (2-3)‡‡
GAD-7 [0 –21]*** 2 (0-11)* 2 (0-8) 5 (0-11)**
Data are presented as absolute number (%) or median (min-max). FVC: forced vital capacity (% predicted), TLCO: diffusing capacity of 
the lung for carbon monoxide (%predicted), 6MWD: distance walked in a 6-minute walk test (meters), SpO2: oxygen saturation from pulse 
oximetry measured during 6MWT, SGRQ: St George’s Respiratory Questionnaire, K-BILD: King’s Brief quality of life questionnaire for 
Interstitial Lung Diseases, GAD-7: Generalized Anxiety Disorder 7-item scale. *: n=22, †: n=17, ‡: n=19, §: n=21, ǁ: n=7, ¶: n=8, **: n=12, 
††: n=10, ‡‡: n=11, §§: SGRQ lower scores indicate better health-related QoL, ǁǁ: K-BILD lower scores indicate worse health-related 
QoL, ¶¶: Assessed with the SGRQ, ***: GAD-7 higher scores indicate more anxiety. 
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Gas exchange parameters showed a tendency toward 
decline with a TLCO at baseline of 50%pred (26-62) 
vs. 45%pred (25-59) in week 18.
We also analyzed the data including the four 
patients that did not cross over; no changes in results 
were found.
Discussion
In this crossover pilot study, we explored the 
feasibility of a home-based walk-bike intervention 
study in IPF patients, and evaluated its effects on 
QoL and exercise capacity.
The feasibility outcomes demonstrate that a 
home-based walk-bike intervention study in its cur-
rent design is difficult to accomplish. Potential bar-
riers for feasibility of the study include reluctance to 
participate in the study, but also external factors such 
as weather and road conditions that may hampered 
adherence to the protocol.  Patients satisfaction with 
the bike greatly varied. Despite the moderate us-
age intensity of the walk-bike, we found a tenden-
cy towards improvement in QoL after the 8-week 
homebased training program with the walk-bike. 
Functional exercise capacity did not change. Mobil-
ity increased with an average of 116 meters in dis-
tance covered when using the walk-bike during the 
6MWT, compared to an unaided regular 6MWT. 
Use of the walk-bike proved to be safe.
A larger future RCT to detect clear walk-bike 
training-effects on QoL and exercise capacity does 
Table 4. Change in health status and exercise measures of patients that completed both phases (N=10)
ΔControl period ΔWalk-bike period
SGRQ *
Total (n=8) 1.2 (-12.3 -  8.3) -7.1 (-17.8 - 5.9)
Symptoms (n=9) 6.7 (-22.7 - 38.9) -7.9 (-42.6 - 16.0)
Activity (n=9) 0.0 (-18.1 - 6.3) -5.2 (-14.2 - 1)
Impact (n=8) 0.3 (-12.3 - 8.9) -7.4 (-22.3 - 9.9)
K-BILD †
Total (n=8) 1.8 (-14.7 - 15.3) 6.5 (-10.0 - 29.4)
Chest (n=8) 0.0 (-25.0 - 25.0) 12.5 (0.0 - 37.5)
Breathlessness & activity (n=9) 0.0 (-29.8 - 14.9) 0.0 (-21.8 - 46.8)
Psychological (n=8) 0.0 (-11.1 - 23.5) 6.2 (-16.1 - 18.5)
Other
GAD-7 (n=9) 0 (-2 - 6) 0 (-2 - 0)
Perceived health status (n=9) ‡ 0 (-2 - 0) 0 (-2 - 2)
Exercise measures
6MWD (m) (n=7) -4 (-25 - 28) -3 (-34 - 23)
Nadir SpO2 (%) (n=7) -1 (-3 - 6) -3 (-7 - 2)
Average steps/day (n=6) 132 (-903 - 3056) -461 (-4335 - 1063)
Data are presented as median (min-max) [n]; FVC:  Forced vital capacity (%predicted), TLCO: transfer capacity of the lung for carbon 
monoxide (%predicted), 6MWD: distance walked during 6-minute walk test, SpO2: oxygen saturation from pulse oximetry, SGRQ:  St 
George’s Respiratory Questionnaire (MID for total score is 7 points) , K-BILD: King’s Brief quality of life questionnaire for Interstitial 
Lung Diseases (MID range for total score is 6-10 points), GAD-7: Generalized Anxiety Disorder 7-item scale. *: A negative change in 
SGRQ score indicates an improvement in health-related QoL, †: A positive change in K-BILD score indicates an improvement in health-
related QoL, ‡: Assessed with the SGRQ.
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not seem feasible unless potential barriers detected 
in our study are being solved. We chose a crossover 
design as it holds the advantage over a parallel study 
that the patient is its own control, thereby reducing 
the influence of confounding variables. However, this 
crossover design warrants a longer duration of study 
for the individual patient (16-18 weeks). Despite the 
block randomization to account for seasonal chang-
es, weather changes during the study period turned 
out to affect the use of the walk-bike. A study incor-
porating both walk-bike use as well as a home-based 
indoor training alternative, maybe a better design for 
a home-based training program. As table 1 shows, 
another potential barrier is the collection of correct 
information of the intensity of training. In our pilot 
study patients recorded the time of walk-bike use in a 
diary. However, this patient-recorded time may have 
included time spent waiting and resting on the bike 
without movement. Accelerometers are devices that 
if worn by the patient, can record intensity duration 
and frequency of activities and makes assessments of 
the potential effects of the walk-bike more accurate. 
Patient satisfaction with the walk-bike varied 
greatly from positive to negative. Patients positively 
evaluated the walk-bike because it enabled them to 
walk further with less dyspnea, or made it possible 
to leave the house again. The feeling of an increased 
level of independence and social participation are 
both important aspects of IPF patients’ QoL (9, 34). 
Negative comments related to being afraid to be 
stigmatized when using the walk-bike. Swigris et al. 
investigated how IPF affects QoL from patients’ per-
spective and noted many patients feel the need to try 
to hide the fact that they have a chronic illness when 
they are in public (34). This aspect, together with un-
familiarity with this new walking-aid, may also have 
Fig. 3. Individual changes in SGRQ- and K-BILD total scores during control and intervention period. A negative change in SGRQ score 
indicates an improvement in health-related quality of life, a positive change in K-BILD score indicates an improvement in health-related 
quality of life
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played a role in the difficult inclusion of patients in 
our study. Other patients noted that the walk-bike 
was too heavy when used outdoors e.g. on hilly roads. 
It might well be that when the road includes obsta-
cles or hills, use of the walk-bike is more compli-
cated, which was also observed in another study (35).
In this pilot study, the use of the walk-bike led to 
improvement of the SGRQ total equal to the mini-
mal important difference (MID) of 7 points, with a 
median difference in change of 8.3 points between 
the intervention period and control period. This im-
provement in SGRQ scores is comparable with the 
effects reported in a recently published systematic re-
view on PR in IPF.(36) Meta-analysis on the results 
of three studies demonstrated a weighted mean dif-
ference SGRQ total score of -8.34 (95% CI, -11.30 
- -5.39; n = 82) between intervention -and control 
groups, favoring PR. In our study, we also assessed 
QoL with the ILD specific K-BILD questionnaire 
and found similar results in magnitude and direction 
of changes compared to the SGRQ. The K-BILD 
holds advantages for clinical use, being much shorter 
and disease specific.
We found no effect in exercise capacity 
(6MWD). In studies that assessed the effect of ex-
ercise training or PR programs in patients with IPF, 
6MWD usually improved (14). The previous men-
tioned review of Gomes-Neto et al. (36) showed a 
weighted mean difference in 6MWD of 44 meters 
(95% CI, 5.3-82.8; n = 113) favoring PR. Most PR- 
or physical training programs contain supervised 
exercise protocols with a combination of endurance 
and resistance training (37). In our walk-bike inter-
vention, the primary aim was to increase QoL. Par-
ticipants were encouraged to use the walk-bike for at 
least one hour daily, and it was up to the discretion 
of the patients whether to use it continuously or in 
intervals. Practical factors such as weather conditions 
and day to day changes in wellbeing turned out to 
limit participants from using the walk-bike strin-
gently and may have minimized the effect on exer-
cise capacity. In patients with severe COPD it was 
shown that interval training at low burden could still 
have a positive effect on exercise capacity (38). We 
hypothesized that by increasing daily activities, pa-
tients would also exercise more at low burden which 
may eventually result in improving or maintaining 
exercise capacity and improving Qol.  
The advantage of a home-based physical exer-
cise program is increasingly recognized (14, 20). It 
remains to be evaluated if a more structured and 
supervised use of the walk-bike could play a role in 
such programs. 
We found a meaningful improvement of 116 
meters in distance covered during a 6MWT with use 
of the walk-bike, compared to an unaided test. This 
is in line with the improvement found by Vaes et al. 
who assessed the effects of the walk-bike on exercise 
performance in COPD patients (23). Improvement 
of mobility by using the walk-bike could potentially 
Fig. 4. Individual differences in 6MWD and lowest SpO2 during 6MWT with and without walk-bike
Effect of the walk-bike on QoL and 6MWT in IPF 201
lead to a higher level of independence and social 
participation. These factors may have been the main 
contributing factors to the tendency toward im-
provement in QoL in our study, even though exercise 
capacity did not improve. 
One of the limitations of our study is the small 
sample size. We aimed to include 22 patients, en-
rolled 23 patients but after randomization, a part of 
the patients did not start or discontinued. Only 10 
patients completed both phases which underlines 
the difficulties encountered when trying to set up 
an interventional study for such a vulnerable pa-
tient group. If patients still had a reasonably well-
preserved exercise tolerance, they did not wish to use 
a walk-bike. On the other side, when patients were 
more impaired and wished to use the walk-bike, risk 
of dropout increased, leaving a small subgroup that 
potentially benefits from this intervention. A poten-
tial limitation of the study design could be a carry-
over effect. However, we believe this can be neglected 
as 8 patients were allocated to the control period in 
the first phase and trained with the walk-bike in the 
second phase, only 2 patient participated in the re-
verse order. Moreover, with gas exchange parameters 
that tended to decline across the study, a potential 
order effect might have led to underestimation of the 
effect of the walk-bike. Furthermore, 2 patients that 
started with the walk-bike decided to continue with 
the walk-bike instead of crossing over to the control 
arm.
In conclusion, this pilot study showed that a 
larger RCT may not be feasible unless most of  the 
potential barriers are being solved. Despite the small 
group studied we found that the use of a walk-bike 
led to a meaningful improvement in QoL for pa-
tients with IPF after an 8-weeks homebased training 
program. Use of the walk-bike also increased mobil-
ity for patients but did not result in an improvement 
in exercise capacity. Patient satisfaction varied greatly 
and the use of the walk-bike seems only beneficial for 
a small selected group of patients with IPF.
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